Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RSLBF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RSLBF and 80,000+ other tickers.
See exactly how RSLBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RSLBF and 80,000+ other tickers.
RaySearch Laboratories AB (publ) is a global medical technology innovator, dedicated to developing advanced software solutions for cancer treatment. Its flagship product, RayStation, serves as a comprehensive treatment planning platform, integrating sophisticated features such as automated planning, adaptive therapy, multi-criteria optimization, and machine learning. This system ensures swift and precise dose calculations, minimizes exposure to organs-at-risk, and accommodates a wide spectrum of radiation modalities, from cutting-edge proton, carbon ion, and boron neutron capture therapies to…
RaySearch Laboratories AB (publ) (RSLBF) Q1 2026 Earnings Call Transcript
RaySearch Laboratories AB (publ) (RSLBF) Q4 2025 Earnings Call Transcript
RaySearch Laboratories AB (publ) (OTCPK:RSLBF) Q3 2025 Earnings Call November 7, 2025 4:00 AM EST Company Participants Carolina Stromlid - Head of Investor Relations Johan Löf - Founder, CEO, President & Director Nina Grönberg Conference Call Participants Mattias Vadsten - SEB, Research Division Kristofer Liljeberg-Svensson - DNB Carnegie, Research Division Presentation Carolina Stromlid Head of Investor Relations Good morning and a warm welcome to the presentation of RaySearch Q3 2025 Results. My name is Carolina Stromlid and I'm new Head of Investor Relations at RaySearch.
STOCKHOLM , Aug. 8, 2025 /PRNewswire/ -- SECOND QUARTER (APRIL - JUNE 2025) Order intake amounted to SEK 241.2 M (290.3) Net sales amounted to SEK 304.9 (318.9) Operating profit amounted to SEK 36.4 M (79.3) Profit after tax amounted to SEK 30.8 M (61.4) Earnings per share before/after dilution amounted to SEK 0.90 (1.79) Cash flow from operating activities amounted to SEK 70.6 M (154.6) Order backlog amounted to SEK 1,665.3 M (1,790.5) at the end of the period HALF-YEAR (JANUARY - JUNE 2025) Order intake amounted to SEK 650.8 M (528.8) Net sales amounted to SEK 636.6 M (576.1) Operating profit amounted to SEK 111.2 M (125.1) Profit after tax amounted to SEK 87.6 M (98.1) Earnings per share before/after dilution amounted to SEK 2.55 (2.86) Cash flow from operating activities amounted to SEK 217.4 M (321.9) SIGNIFICANT EVENTS DURING THE SECOND QUARTER Odense University Hospital in Denmark has placed an order and is increasing the level of automation with the RayStation treatment planning system. In May, RayStation v2025 was launched, featuring fast automated treatment planning using machine learning* and the ECHO algorithm, as well as expanded support for treatment planning for patients in the upright position.
STOCKHOLM , May 9, 2025 /PRNewswire/ -- FIRST QUARTER (JANUARY - MARCH 2025) Order intake amounted to SEK 409.6 M (238.5) Net sales amounted to SEK 331.7 M (257.2) Operating profit amounted to SEK 74.8 M (45.8) Profit after tax amounted to SEK 56.8 M (36.7) Earnings per share before/after dilution amounted to SEK 1.66 (1.07) Cash flow from operating activities amounted to SEK 146.8 M (167.3) Order backlog amounted to SEK 1,734.4 M (1,848.0) at the end of the period. SIGNIFICANT EVENTS DURING THE FIRST QUARTER The number of radiation therapy clinics worldwide that have chosen RayStation now exceeds 1,100.